

血清SCC-Ag、CYFRA21-1及VEGF水平与宫颈癌临床病理特征及预后的关系

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年08期 页码: 1395-1399 栏目: 论著(妇科肿瘤) 出版日期: 2019-03-08

Title: The relationship between serum SCC-Ag,CYFRA21-1 and VEGF and the clinicopathological features and prognosis of cervical cancer

作者: 林元; 苏红娥; 符春丽; 薛万兴; 王慧玲
海南西部中心医院妇产科, 海南 儋州 571799

Author(s): Lin Yuan; Su Honge; Fu Chunli; Xue Wanxing; Wang Huiling
Department of Obstetrics and Gynecology, Central Hospital of Western Hainan, Hainan Danzhou 571799, China.

关键词: 鳞状细胞癌抗原; 细胞角蛋白19片段; 血管内皮生长因子; 宫颈癌; 预后

Keywords: squamous cell carcinoma antigen; cytokeratin 19 fragment; vascular endothelial growth factor; cervical cancer; prognostic

分类号: R737.33

DOI: 10.3969/j.issn.1672-4992.2019.08.026

文献标识码: A

摘要: 目的:探讨血清鳞状细胞癌抗原(SCC-Ag)、细胞角蛋白19片段抗原(CYFRA21-1)及血管内皮生长因子(VEGF)水平与宫颈癌临床病理特征及预后的关系。方法:选取2010年1月至2012年12月海南西部中心医院收治的146例宫颈癌患者、50例宫颈上皮内瘤病变(CIN)患者(CIN组)和50例正常健康女性(对照组),比较各组血清SCC-Ag、CYFRA21-1及VEGF水平。分析宫颈癌患者血清SCC-Ag、CYFRA21-1及VEGF水平与临床病理特征的关系,采用Kaplan-Meier法分析不同临床病理特征患者生存率差异,多因素COX比例风险回归模型分析宫颈癌患者预后的影响因素。结果:宫颈癌组血清SCC-Ag、CYFRA21-1及VEGF水平均明显高于CIN组和对照组 [SCCA (ng/ml) : 9.04±2.35 vs 1.91±0.62和0.65±0.14; CYFRA21-1 (ng/ml) : 5.48±1.62 vs 0.92±0.43和0.64±0.25; VEGF (pg/ml) : 326.42±48.15 vs 125.48±23.60和108.62±18.73, 均P<0.01]。血清SCC-Ag、CYFRA21-1及VEGF水平与宫颈癌患者的临床分期、病理分级、淋巴结转移、浸润深度及脉管浸润相关(P<0.05)。单因素及多因素COX回归分析显示,临床分期 [HR (95%CI) : 2.016 (1.512~2.915)]、淋巴结转移 [HR (95%CI) : 4.013 (2.937~6.016)]、SCC-Ag [HR (95%CI) : 2.972 (2.106~4.618)]、CYFRA21-1 [HR (95%CI) : 1.704 (1.335~2.519)]及VEGF [HR (95%CI) : 2.116 (1.685~3.164)]阳性表达是宫颈癌患者预后不良的危险因素。结论:宫颈癌患者血清SCC-Ag、CYFRA21-1及VEGF水平明显升高,SCC-Ag、CYFRA21-1及VEGF阳性表达是影响宫颈癌患者预后不良的危险因素。

Abstract: Objective: To investigate the relationship between serum squamous cell carcinoma antigen (SCC-Ag), cytokeratin 19 fragment antigen (CYFRA21-1) and vascular endothelial growth factor (VEGF) and clinicopathological characteristics and prognosis of cervical cancer. Methods: One hundred and forty-six cases of cervical cancer, 50 cases of cervical intraepithelial neoplasia (CIN) and 50 normal healthy women (control group) were selected from January 2010 to December 2012 in Central Hospital of Western Hainan. The serum levels of SCC-Ag, CYFRA21-1 and VEGF were compared in each group. The relationship between serum SCC-Ag, CYFRA21-1 and VEGF levels and clinicopathological features in patients with cervical cancer was analysed. The survival rate of patients with different clinicopathological characteristics was analyzed by Kaplan-Meier method. Multivariate COX proportional hazards regression model was used to analyze the prognostic factors of cervical cancer. Results: The serum levels of SCC-Ag, CYFRA21-1 and VEGF in the cervical cancer group were significantly higher than those in the group CIN and the control group [SCCA (ng/ml) : 9.04±2.35 vs 1.91±0.62 and 0.65±0.14. CYFRA21-1 (ng/ml) : 5.48±1.62 vs 0.92±0.43 and 0.64±0.25. VEGF (pg/ml) : 326.42±48.15 vs 125.48±23.60 and 108.62±18.73, all P<0.01]. Serum levels of SCC-Ag, CYFRA21-1 and VEGF were associated with clinical staging, pathological grading, lymph node metastasis, depth of infiltration and vascular infiltration

in patients with cervical cancer ($P < 0.05$). Univariate and multivariate COX regression analysis showed that clinical stage [HR(95%CI):2.016(1.512-2.915) and lymph node metastasis [HR(95%CI):4.013(2.937-6.016), SCC-Ag [HR(95%CI):2.972(2.106-4.618), CYFRA21-1 [HR(95%CI):1.704(1.335-2.519)] and VEGF [HR(95%CI):2.116(1.685-3.164)] positive expression were the risk factors of poor prognosis of patients with cervical cancer. Conclusion: The levels of serum SCC-Ag, CYFRA21-1 and VEGF in cervical cancer patients increased significantly, and the positive expressions of SCC-Ag, CYFRA21-1 and VEGF were risk factors affecting the prognosis of patients with cervical cancer.

参考文献/REFERENCES

- [1] Elmajjaoui S, Ismaili N, El Kacemi H, et al. Epidemiology and outcome of cervical cancer in national institute of Morocco [J]. *BMC Womens Health*, 2016, 16(1):62.
- [2] Lekskul N, Charakorn C, Lertkhachonsuk AA, et al. The level of squamous cell carcinoma antigen and lymph node metastasis in locally advanced cervical cancer [J]. *Asian Pac J Cancer Prev*, 2015, 16(11):4719-4722.
- [3] Piao X, Kong TW, Chang SJ, et al. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases [J]. *Gynecol Oncol*, 2015, 138(1):89-93.
- [4] Sharma M, Piplani S, Madan M, et al. Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital [J]. *Indian J Pathol Microbiol*, 2017, 60(4):469-474.
- [5] Zhou Ying, Jiang Jiyong. The relationship between lymphatic space infiltration and clinicopathological factors and prognosis in early cervical cancer [J]. *Journal of Practical Obstetrics and Gynecology*, 2018, 34(3):203-207. [周滢, 姜继勇. 早期宫颈癌淋巴管间隙浸润与临床病理因素及预后的关系 [J]. *实用妇产科杂志*, 2018, 34(3):203-207.]
- [6] Feng JF, Chen S, Yang X. Combination of c-reactive protein and squamous cell carcinoma antigen in predicting postoperative prognosis for patients with squamous cell carcinoma of the esophagus [J]. *Oncotarget*, 2017, 8(38):63132-63139.
- [7] Cho A, Hur J, Hong YJ, et al. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer [J]. *Tumour Biol*, 2016, 37(3):3205-3213.
- [8] Li Longfei, Qu Jingming, Wang Xiangjun, et al. Expression and significance of serum CEA, NSE and CYFRA21-1 in different types of lung cancer patients before and after chemotherapy [J]. *Chin J Gerontol*, 2018, 38(4):821-823. [李龙飞, 渠敬明, 王祥军, 等. 不同类型肺癌患者化疗前后血清CEA、NSE及CYFRA21-1的表达及意义 [J]. *中国老年学杂志*, 2018, 38(4):821-823.]
- [9] Nakamura T, Ide H, Eguchi R, et al. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus [J]. *Dis Esophagus*, 2017, 11(1):35-39.
- [10] Naikoo NA, Dil-Afroz, Rasool R, et al. Upregulation of vascular endothelial growth factor (VEGF), its role in progression and prognosis of non-small cell lung carcinoma [J]. *Cancer Genet*, 2017, 216(10):67-73.
- [11] Soukup V, Capoun O, Pesl M, et al. Placental growth factor in bladder cancer compared to the diagnostic accuracy and prognostic performance of vascular endothelial growth factor A [J]. *Anticancer Res*, 2018, 38(1):239-246.
- [12] Xu D, Wang D, Wang S, et al. Correlation between squamous cell carcinoma antigen level and the clinicopathological features of early-stage cervical squamous cell carcinoma and the predictive value of squamous cell carcinoma antigen combined with computed tomography scan for lymph node metastasis [J]. *Int J Gynecol Cancer*, 2017, 27(9):1935-1942.
- [13] Zhou Z, Li W, Zhang F, et al. The value of squamous cell carcinoma antigen (SCCA) to determine the lymph nodal metastasis in cervical cancer: A meta-analysis and literature review [J]. *PLoS One*, 2017, 12(12):e0186165.
- [14] Sun H, Tang F, Zhou S, et al. Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis [J]. *J Obstet Gynaecol Res*, 2016, 42(10):1310-1316.
- [15] Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, et al. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease [J]. *Tumour Biol*, 2016, 37(1):1271-1278.
- [16] Yin Hongzhang, Zhang Lianpeng. Clinical analysis of serum CYFRA21-1, TPS, CA125 and CEA expression in cervical cancer patients [J]. *Modern Oncology*, 2015, 23(20):3018-3020. [尹红章, 章莲蓬. 宫颈癌患者血清CYFRA21-1、TPS、CA125和CEA表达的临床分析 [J]. *现代肿瘤医学*, 2015, 23(20):3018-3020.]
- [17] Kornovski Y, Ismail E, Slavchev S. Lymph node metastases and disease-free survival in cervical cancer patients [J]. *Akush Ginekol(Sofiiia)*, 2013, 52(2): 9-13.
- [18] Kasuya G, Ogawa K, Ibrah S, et al. Postoperative radiotherapy for uterine cervical cancer: impact of lymph node and histological type on survival [J]. *Anticancer Res*, 2013, 33(5): 2199-2204.
- [19] Guo S, Yang B, Liu H, et al. Serum expression level of squamous cell carcinoma antigen, highly sensitive C-reactive protein, and CA-125 as potential biomarkers for recurrence of cervical cancer [J]. *J Cancer Res Ther*, 2017, 3(4):689-692.
- [20] Chen Xiaolu, Zhang Bo, Wu Rongyi. The prognostic value of CK2beta, VEGF and p53 protein expression in patients with cervical cancer [J]. *Chongqing Medical Science*, 2016, 45(8):1083-1086. [陈晓露, 张波, 吴蓉宜. CK2B、VEGF和p53蛋白表达对宫颈癌患者预后的预测价值研究 [J]. *重庆医学*, 2016, 45(8):1083-1086.]

备注/Memo: 海南省医学科研基金资助 (编号: 17A200685)

更新日期/Last Update: 1900-01-01